Dr. Flinn Discusses the Efficacy of IPI-145 in CLL

Video

Ian W. Flinn, MD, PhD, from the Sarah Cannon Research Institute, discusses the preliminary efficacy of IPI-145 in patients with chronic lymphocyic leukemia (CLL).

Ian W. Flinn, MD, PhD, from the Sarah Cannon Research Institute, discusses the preliminary efficacy of IPI-145 in patients with chronic lymphocyic leukemia (CLL).

IPI-145 is a potent oral inhibitor PI3K-delta and -gamma that was examined in a phase I trial that enrolled 44 patients with relapsed or refractory CLL. Overall, there was a 47% overall response rate, as evaluated by modified IWCLL criteria, in a heavily pretreated population of patients with CLL, Flinn notes. Additionally, there was a 50% response rate even in patients with 17p deletions or TP53 mutation.

When considering the mild toxicity profile along with the efficacy, IPI-145 represents a very promising new treatment option, Flinn notes. As a result, IPI-145 will be further examined in a phase III trial in comparison to ofatumumab.

<<<

View more from the 2013 ASH Annual Meeting

Related Videos
John N. Allan, MD
Nicole Lamanna, MD
Adrienne Phillips, MD, MPH
Joseph P. McGuirk, DO, an expert on lymphoma
Joseph P. McGuirk, DO, an expert on lymphoma
Shridar Ganesan, MD, PhD
M. Hamza Habib, MD, JD, MBA, FACP, FAAHPM, FRCPI, MRCP,
Patrick Boland, MD
Joseph P. McGuirk, DO, an expert on lymphoma
Joseph P. McGuirk, DO, an expert on lymphoma